Professor Johann de Bono key publications
Robinson, D., Van Allen, EM., Wu, YM., Schultz, N., Lonigro, RJ., Mosquera, JM., Montgomery, B., Taplin, ME., Pritchard, CC., Attard, G., et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell, Vol.161, pp.1215–1228, Show Abstract
Fizazi, K., Scher, HI., Miller, K., Basch, E., Sternberg, CN., Cella, D., Forer, D., Hirmand, M. & de Bono, JS. (2014) Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol, Vol.15, pp.1147–1156, Show Abstract
Omlin, A., Pezaro, C., Mukherji, D., Mulick Cassidy, A., Sandhu, S., Bianchini, D., Olmos, D., Ferraldeschi, R., Maier, G., et al. (2013) Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol, Vol.64, pp.300–306, Show Abstract
Ryan, CJ., Smith, MR., de Bono, JS., Molina, A., Logothetis, CJ., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, JM., Ng, S., et al. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, Vol.368, pp.138-148, Show Abstract
Logothetis, CJ., Basch, E., Molina, A., Fizazi, K., North, SA., Chi, KN., Jones, RJ., Goodman, OB., Mainwaring, PN., Sternberg, CN., et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol, Vol.13, pp.1210–1217, Show Abstract
Olmos, D., Brewer, D., Clark, J., Danila, DC., Parker, C., Attard, G., Fleisher, M., Reid, AH., Castro, E., Sandhu, SK., et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol, Vol.13, pp.1114–1124, Show Abstract
Scher, HI., Fizazi, K., Saad, F., Taplin, ME., Sternberg, CN., Miller, K., de Wit, R., Mulders, P., Chi, KN., Shore, ND., et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, Vol.367, pp.1187–1197, Show Abstract
de Bono, JS., Logothetis, CJ., Molina, A., Fizazi, K., North, S., Chu, L., Chi, KN., Jones, RJ., Goodman, OB Jr., Saad, F., et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, Vol.364, pp.1995–2005, Show Abstract
de Bono, JS. & Ashworth, A. (2010) Translating cancer research into targeted therapeutics. Nature, Vol.467, pp.543–549, Show Abstract
de Bono, JS., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, JP., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, MJ., Shen, L., et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, Vol.376, pp.1147–1154, Show Abstract
Reid, AH., Attard, G., Danila, DC., Oommen, NB., Olmos, D., Fong, PC., Molife, LR., Hunt, J., Messiou, C., Parker, C., et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, Vol.28, pp.1489–1495, Show Abstract
Fong, PC., Boss, DS., Yap, TA., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, MJ., et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, Vol.361, pp.123–134, Show Abstract